Proceedings of the National Academy of Sciences · 2004 · 339 citations · 22 references
Life SciencesMedicinal ChemistryPharmacologyCell SignalingInflammationMolecular PharmacologyChemokine SignalingInflammatory Cell ResponsesInflammatory SignalingLigand BindingLigand-receptor InteractionsReceptor-ligand InteractionsChemokine FunctionChemokine PharmacologyChemokine Receptor AntagonismChemokine Receptor PharmacologyChemokine-induced ActivationInflammatory ChemokinesMyocardial Ischemia-reperfusion InjuryReceptors
The chemokine CXC ligand 8 (CXCL8)/IL-8 and related agonists recruit and activate polymorphonuclear cells by binding the CXC chemokine receptor 1 (CXCR1) and CXCR2. Here we characterize the unique mode of action of a small-molecule inhibitor (Repertaxin) of CXCR1 and CXCR2. Structural and biochemical data are consistent with a noncompetitive allosteric mode of interaction between CXCR1 and Repertaxin, which, by locking CXCR1 in an inactive conformation, prevents signaling. Repertaxin is an effective inhibitor of polymorphonuclear cell recruitment in vivo and protects organs against reperfusion injury. Targeting the Repertaxin interaction site of CXCR1 represents a general strategy to modulate the activity of chemoattractant receptors.
22
DELAYED GRAFT FUNCTION: RISK FACTORS AND IMPLICATIONS FOR RENAL ALLOGRAFT SURVIVAL1
Akinlolu Ojo, Robert A. Wolfe, Philip J. Held et al. · Transplantation · 1997 · 995 citations
PubMed · 1997 · 603 citations
Tatjana Dragic, Alexandra Trkola, Daniah A. D. Thompson et al. · Proceedings of the National Academy of Sciences · 2000 · 427 citations · Full text